QV Bioelectronics USA cooperation feasibility study

胶质母细胞瘤是最常见和侵袭性的原发性成人脑癌。全球发病率为3-5/10万人，并且正在上升，约为3000人英国诊断/年。此病无法治愈，患者在确诊后的平均预期寿命只有14个月。电场治疗是肿瘤切除后应用的一种新的癌症治疗形式，它直接干扰细胞分裂，减缓肿瘤复发，延长生命。然而，由于患者生活质量差和成本效益低，NICE不建议将胶质母细胞瘤单一上市设备用于NHS。QV生物电子（QVB）正在开发GRACE，一种新型植入物，以局部和连续的方式提供电场治疗，可能使胶质母细胞瘤患者的预期寿命翻倍，导致潜在的改善患者的结果，同时克服与现有解决方案相关的生活质量问题。QVB正在寻求美国的合作伙伴，他们拥有专业知识、技术和资金，可以将GRACE设备推向市场。QVB的设备仍处于临床前开发阶段，在几年内不会准备好给患者开处方。QVB的技术将在未来扩展到其他类型的脑肿瘤，创造一个价值超过50亿英镑/年的全球市场机会，同时为NHS患者提供一种新的治疗方法。这将为英国创造就业机会，并有助于巩固英国在不断发展的生物电子学领域作为全球领导者的地位。

Glioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and patient life expectancy is just 14-months post-diagnosis on average.Electric field therapy is a new form of cancer treatment applied after tumour resection that directly interferes with cell division, slowing tumour recurrence and prolonging life. However, the single marketed device for glioblastoma is not recommended for use on the NHS by NICE due to poor patient quality-of-life and low cost-effectiveness.QV Bioelectronics (QVB) are developing GRACE, a novel implant that delivers electric field therapy in a focal and continuous manner, potentially doubling glioblastoma patient life expectancy, leading to potential improved patient outcomes whilst overcoming quality-of-life issues associated with existing solutions. QVB is seeking to access partners in the US who have specialist knowledge, technologies and capital available to bring the GRACE device to market. QVB's device is still undergoing pre-clinical development and will not be ready to be prescribed to patients for several years. QVB's technology will be expanded to other types of brain tumours in future, creating a combined global market opportunity worth over £5Bn/year, whilst providing a new treatment for NHS patients. This will generate UK jobs and help to cement the UK's position as global leaders in the growing field of bioelectronics.